PE-22-28

Overview

PE-22-28 is a synthetic heptapeptide derived from a larger endogenous peptide called spadin (the 12-44 fragment of sortilin propeptide). Developed through structure-activity relationship studies led by Dr. Marc Bharat and colleagues at the Institut de Pharmacologie Moleculaire et Cellulaire (IPMC) in France, PE-22-28 represents an optimized, truncated form of spadin designed to retain full biological activity while improving pharmacological properties.

The compound acts by blocking TREK-1 (TWIK-related potassium channel-1), a two-pore domain potassium channel expressed prominently in the central nervous system. TREK-1 gained attention as a novel antidepressant target following the discovery that TREK-1 knockout mice display a depression-resistant phenotype — they behave as though they are on antidepressant medication across multiple behavioral paradigms.

Spadin, the parent molecule, was identified as an endogenous TREK-1 blocker and demonstrated antidepressant-like effects in rodent models with a notably rapid onset (4 days versus the 2-3 weeks typical of conventional antidepressants). PE-22-28 was subsequently developed as a more potent and metabolically stable variant, containing only the seven amino acids critical for TREK-1 binding.

As of 2026, PE-22-28 remains a preclinical research compound. No human clinical trials have been conducted, and all published data originates from in vitro studies and rodent behavioral experiments.

Structure and Sequence

PE-22-28 is a linear heptapeptide corresponding to residues 22 through 28 of the mature spadin sequence:

Trp-Pro-Arg-Pro-Gln-Ile-Ile (WRPQII with preceding W)

• Molecular formula: C₄₆H₇₃N₁₁O₈
• Molecular weight: approximately 912 g/mol
• Parent compound: Spadin (sortilin propeptide fragment 12-44, a 33-amino-acid peptide)

Key structural features:

• The tryptophan (Trp) residue at the N-terminus is critical for TREK-1 channel interaction
• The proline-arginine-proline motif provides conformational rigidity
• The C-terminal isoleucine-isoleucine dipeptide contributes to hydrophobic membrane interactions
• Various analogs with D-amino acid substitutions and N-methylation have been explored to improve metabolic stability

Mechanism of Action

TREK-1 Channel Blockade

TREK-1 is a background potassium leak channel that contributes to setting the resting membrane potential of neurons. When TREK-1 channels are open, they hyperpolarize the neuron, making it less excitable. PE-22-28 blocks TREK-1 channels, resulting in:

• Neuronal depolarization — increased resting membrane potential toward the firing threshold
• Enhanced excitability — reduced threshold for action potential generation
• Increased neurotransmitter release — particularly serotonin and norepinephrine in mood-relevant brain regions

TREK-1 channels are highly expressed in the hippocampus, prefrontal cortex, amygdala, and dorsal raphe nucleus — brain regions centrally involved in mood regulation, memory, and emotional processing.

Neurogenesis Stimulation

TREK-1 blockade by PE-22-28 and spadin has been associated with increased hippocampal neurogenesis in rodent studies. This effect is proposed to involve:

• Increased BDNF expression in the hippocampus
• Enhanced proliferation of neural progenitor cells in the subgranular zone of the dentate gyrus
• Improved survival and integration of newborn neurons
• Activation of the CREB signaling pathway

Rapid-Onset Mechanism

Unlike SSRIs, which require weeks of chronic administration before clinical benefit, TREK-1 blockers demonstrate behavioral effects in rodent models within 4 days. This rapid onset is hypothesized to result from the direct mechanism of action: rather than gradually shifting serotonin transporter occupancy and receptor desensitization, TREK-1 blockade immediately alters neuronal excitability in mood-regulatory circuits.

Selectivity Profile

PE-22-28 shows selectivity for TREK-1 over other two-pore domain potassium channels (TREK-2, TRAAK, TASK). This selectivity is pharmacologically significant because TREK-2 and TRAAK have distinct tissue distributions and functions, and nonselective blockade could produce unwanted peripheral effects.

Research Summary

Area	Model	Key Finding	Reference
Antidepressant activity	Forced swim test (mice)	Reduced immobility time comparable to fluoxetine, with onset at 4 days	Djillani et al., 2017
TREK-1 blockade	Patch clamp electrophysiology	IC₅₀ in the low nanomolar range for TREK-1 current inhibition	Djillani et al., 2017
Neurogenesis	BrdU incorporation in mouse hippocampus	Increased hippocampal neurogenesis after 4 days of treatment	Mazella et al., 2010 (spadin)
Corticosterone effects	Stressed mice (chronic mild stress)	Reduction in stress-induced corticosterone elevation	Djillani et al., 2017
Channel selectivity	Two-pore potassium channel panel	Selective for TREK-1 over TREK-2, TRAAK, and TASK channels	Djillani et al., 2017
Metabolic stability	In vitro serum stability	Improved resistance to proteolytic degradation vs. full-length spadin	Djillani et al., 2017
Anxiolytic effects	Elevated plus maze (mice)	Increased time in open arms, suggesting reduced anxiety-like behavior	Moha Ou Maati et al., 2012 (spadin)

Pharmacokinetics

• Administration routes studied: Intravenous and intraperitoneal injection in rodent models; intranasal delivery has been discussed but not extensively published
• Blood-brain barrier penetration: Inferred from behavioral efficacy following systemic administration
• Half-life: Improved over spadin, though exact values vary by route; spadin has a plasma half-life of approximately 25 minutes, and PE-22-28's structural modifications are designed to extend this
• Effective doses (animal): Typically studied at 0.1-1 mg/kg in mouse behavioral paradigms
• Metabolic vulnerability: The arginine residue may be susceptible to trypsin-like proteases; various modifications have been explored to address this

The compound's peptide nature presents typical challenges for oral bioavailability, and published research has primarily utilized injectable routes of administration.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Parameter	Value
Vial size	10 mg
Bacteriostatic water	3.0 mL
Concentration	~3,333 mcg/mL
Storage (reconstituted)	2-8 °C, use within 4 weeks
Storage (lyophilized)	-20 °C

Dosing Schedule

Phase	Dose	Frequency	Duration
Starting	50 mcg	Once daily	Weeks 1-2
Standard	100 mcg	Once daily	Weeks 3-8
Escalation (optional)	150 mcg	Once daily	Weeks 9-12
Advanced (optional)	200 mcg	Once daily	Weeks 13-16

Syringe Measurements (U-100 insulin syringe)

Dose	Units	Volume
50 mcg	1.5 units	0.015 mL
100 mcg	3 units	0.03 mL
150 mcg	4.5 units	0.045 mL
200 mcg	6 units	0.06 mL

Cycle Guidelines

• Cycle length: 8-16 weeks
• Route: Subcutaneous injection
• Timing: Consistent daily timing
• Injection sites: Rotate between abdomen, thighs, and upper arms (injection site rotation)
• Tip: For small-volume doses (under 10 units), use 30- or 50-unit syringes for improved accuracy (syringe selection)

Common Discussion Topics

Comparison to Conventional Antidepressants

The rapid-onset profile of TREK-1 blockers is one of the most discussed aspects of this research area. Conventional SSRIs and SNRIs typically require 2-4 weeks before therapeutic benefits emerge, while TREK-1 blockade produces behavioral effects in rodent models within days. Whether this rapid onset translates to clinical practice remains unknown, as no human studies have been conducted.

Relationship to Spadin

PE-22-28 is often discussed alongside its parent compound spadin. While spadin was the first identified endogenous TREK-1 blocker, PE-22-28 offers practical advantages as a research tool: it is shorter (7 vs. 33 amino acids), easier to synthesize, more metabolically stable, and retains comparable potency at TREK-1. Some discussions incorrectly conflate findings from spadin studies with PE-22-28 specifically; while the mechanism is shared, the compounds have distinct pharmacokinetic profiles.

Neurogenesis vs. Rapid Onset Paradox

An interesting discussion point is the apparent contradiction between PE-22-28's neurogenic effects and its rapid behavioral onset. Neurogenesis requires weeks for new neurons to mature and integrate into circuits, yet behavioral effects appear within days. This suggests the rapid antidepressant-like effects are mediated by acute changes in neuronal excitability and neurotransmitter release, while neurogenesis may contribute to sustained, longer-term effects — a model similar to what has been proposed for ketamine.

Limited Independent Replication

Much of the PE-22-28 and spadin literature originates from research groups at IPMC in France. While the work is peer-reviewed and the TREK-1 knockout phenotype has been independently confirmed, broader replication of the pharmacological findings by independent laboratories would strengthen the evidence base.

Related Compounds

• Dihexa — Another synthetic peptide studied for cognitive effects through a different mechanism (HGF/c-Met)
• Cerebrolysin — A neurotrophic peptide mixture with overlapping interest areas in neuroplasticity
• Oxytocin — A neurohormone with mood-regulatory properties studied via intranasal administration